Dose-escalating ruxolitinib for refractory hemophagocytic lymphohistiocytosis

BackgroundHemophagocytic lymphohistiocytosis (HLH) is a severe disorder characterized by excessive secretion of cytokines. Even with the recommended HLH-94/2004 regimen, over 30% of patients remain refractory to frontline therapy or relapse after an initial response, leading to poor clinical outcome...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Yue Song, Xiaoli Li, Xuefeng He, Fei Zhou, Feng Du, Ziyan Wang, Suning Chen, Depei Wu
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Frontiers Media S.A. 2023-06-01
Edice:	Frontiers in Immunology
Témata:	ruxolitinib JAK1/2 inhibitor cytokines hemophagocytic lymphohistiocytosis dose-escalating salvage therapy
On-line přístup:	https://www.frontiersin.org/articles/10.3389/fimmu.2023.1211655/full
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!